Atea Pharmaceuticals Inc. (AVIR) Phase 2 MOONSONG Trial Evaluating AT-527 in the Outpatient Setting Did Not Meet the Primary Endpoint
Go back to Atea Pharmaceuticals Inc. (AVIR) Phase 2 MOONSONG Trial Evaluating AT-527 in the Outpatient Setting Did Not Meet the Primary Endpoint| (NASDAQ: AVIR) | Delayed: 4.98 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.98 | 52 Week High | $2.00 | |||
| Open | $4.98 | 52 Week Low | $1.15 | |||
| Day High | $4.98 | P/E | N/A | |||
| Day Low | $4.98 | EPS | $0.00 | |||
| Volume | 9 | |||||
